Search Results
Your search for ,sIX matches 2897 pages
Showing 401 - 450IMbrave050 Trial: Adjuvant Regimen of Atezolizumab Plus Bevacizumab in Resectable Hepatocellular Carcinoma
Adjuvant treatment with the combination of atezolizumab and bevacizumab achieved a statistically significant and clinically meaningful improvement in recurrence-free survival compared with active surveillance alone in patients with high-risk hepatocellular carcinoma following curative-intent...
Organizations Team Up to Improve Cancer Care in Rural Appalachia
The Appalachian Community Cancer Alliance (ACCA) has launched a lung cancer screening initiative to improve cancer care in rural Appalachia. Home to nearly 26 million people, the Appalachian region includes all of West Virginia and parts of 12 other states, and it has a 10% higher cancer mortality...
Implantable Ultrasound Device to Open Blood-Brain Barrier for Peritumoral Delivery of Albumin-Bound Paclitaxel in Recurrent Glioblastoma
In a small single-institution phase I trial reported in The Lancet Oncology, Sonabend et al found that an implantable device for low-intensity pulsed ultrasound with concomitant administration of intravenous microbubbles (LIPU-MB) may be safely used to open the blood-brain barrier to permit...
Cancer-Specific Mortality Rates Vary Widely Across the Globe, Study Finds
Investigators have found that in the majority of countries studied, the recent mortality rates for all major cancer types have decreased except for lung cancer among female patients and hepatic cancer among male patients—where increasing rates were observed in most countries, according to a novel...
Phase II Trial of Guadecitabine Plus Atezolizumab in Patients With Metastatic Bladder Cancer
Although hypomethylating agents previously appeared to be a promising treatment option for patients with bladder cancer refractory to immunotherapy, researchers were forced to halt a recent phase II clinical trial after patients experienced either no response to treatment or rapid tumor...
Addition of Short-Term ADT to Dose-Escalated Radiotherapy in Intermediate-Risk Prostate Cancer
As reported in the Journal of Clinical Oncology by Daniel J. Krauss, MD, and colleagues, the phase III NRG Oncology/RTOG 0815 study showed no significant improvement in overall survival with the addition of short-term androgen-deprivation therapy (ADT) to dose-escalated radiotherapy in patients...
Adding Azacitidine to Standard Chemotherapy May Be Effective for Patients With PTCL-TFH
Researchers have found that azacitidine may be capable of increasing the effectiveness of chemotherapy and aiding nearly 90% of patients who had peripheral T-cell lymphoma with the T follicular helper cell phenotype (PTCL-TFH) achieve remission, according to a novel study published by Ruan et al in ...
Ibrutinib and Rituximab vs Fludarabine, Cyclophosphamide, and Rituximab in Previously Untreated Patients With CLL
As reported in The Lancet Oncology by Peter Hillmen, MBChB, PhD, and colleagues, an interim analysis of the UK phase III FLAIR trial has shown significantly improved progression-free survival with ibrutinib and rituximab vs fludarabine, cyclophosphamide, and rituximab (FCR) in previously untreated...
Abiraterone Acetate Plus Prednisolone With or Without Enzalutamide in Patients With Metastatic Prostate Cancer Initiating ADT
In an analysis of the final results of two STAMPEDE platform phase III trials reported in The Lancet Oncology, Gerhardt Attard, PhD, and colleagues found that the addition of enzalutamide to abiraterone plus prednisolone did not appear to improve survival outcomes and was associated with worse...
Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...
Addition of Tislelizumab to Chemotherapy in First-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
As reported in The Lancet Oncology by Xu et al, an interim analysis of the phase III RATIONALE-306 trial has shown improved overall survival with the addition of the anti–PD-1 antibody tislelizumab to chemotherapy in the first-line treatment of advanced or metastatic esophageal squamous cell...
Remote Outreach May Increase Uptake of and Adherence to Cancer Screenings in Females in Rural Settings
Females in rural areas may be six times more likely to receive timely breast, cervical, and colorectal cancer screenings with remote outreach that involves interactive education and follow-up support by telephone compared with females in rural areas who don’t have remote outreach, according to a...
In BRCA-Mutated Ovarian Cancer, Neoadjuvant Olaparib Feasible, Appears Effective in Pilot Study
Encouraging outcomes were achieved in patients with BRCA-mutated ovarian cancer who received neoadjuvant treatment with olaparib in a feasibility study led by Shannon N. Westin, MD, MPH, Professor in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD...
GOG 258 Final Results: No Improvement in Survival by Adding Radiotherapy to Chemotherapy in Advanced Endometrial Cancer
The long-running randomized NRG Oncology GOG-258 clinical trial failed to identify an overall survival benefit with adjuvant chemoradiotherapy vs chemotherapy alone in any subgroup of patients with locally advanced endometrial cancer. After a median follow-up of 112 months, the hazard ratio for...
Study Explores Impact of Radiation Therapy on Immune Cells and Tumor Cells in Renal Cell Carcinoma
Researchers may have shed light on how radiation therapy impacts immune cells and tumor cells in renal cell carcinoma, according to a novel study published by Chow et al in the Journal for ImmunoTherapy of Cancer. The new findings may provide key information for planning treatment regimens that...
Third-Line Treatment of Follicular Lymphoma
This is Part 3 of Advances in Follicular Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Stephen M. Ansell, Loretta J. Nastoupil, and Gilles Salles discuss the third-line treatment of follicular lymphoma. The patient...
Recurrent Follicular Lymphoma
This is Part 2 of Advances in Follicular Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Stephen M. Ansell, Loretta J. Nastoupil, and Gilles Salles discuss the management of recurrent follicular lymphoma. The patient...
Using Circulating Tumor DNA to Predict Early Recurrence of Soft-Tissue Sarcomas
Circulating tumor DNA (ctDNA) may transform disease monitoring and guide treatment for soft-tissue sarcomas, according to data presented at the 2023 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care.1 Findings of a retrospective review showed that 85% of patients...
Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...
Extreme Poverty May Be a Key Driver for Relapse in Pediatric Patients With ALL
Pediatric patients with acute lymphoblastic leukemia (ALL) living in extreme poverty and undergoing maintenance therapy may have almost a twofold greater risk of relapse compared with pediatric patients who weren’t living in extreme poverty, according to a new study published by Wadhwa et al in...
Neoadjuvant Trabectedin and Radiotherapy in Myxoid Liposarcoma
In the phase II TRASTS study reported in JAMA Oncology, Sanfilippo et al found that neoadjuvant trabectedin and radiotherapy did not meet the target objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) in patients with myxoid liposarcoma but did exhibit activity...
FDA Approves Polatuzumab Vedotin-piiq Plus R-CHP for Previously Untreated DLBCL–Not Otherwise Specified and High-Grade B-Cell Lymphoma
On April 19, the U.S. Food and Drug Administration (FDA) approved the antibody-drug conjugate polatuzumab vedotin-piiq (Polivy) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for previously untreated adult patients who have diffuse large B-cell lymphoma (DLBCL)–not...
Immune Checkpoint Inhibition and Long-Term Survival in Patients With Metastatic Urothelial Cancer
In an analysis reported in JAMA Network Open, Zhu et al found that immune checkpoint inhibitor treatment did not appear to be associated with long-term survival in patients with metastatic urothelial cancer. Study Details The analysis included data from six trials of pembrolizumab, avelumab, and...
FDA Approves Omidubicel-onlv to Reduce Time to Neutrophil Recovery and Infection in Patients With Hematologic Malignancies
On April 17, the U.S. Food and Drug Administration (FDA) approved omidubicel-onlv (Omisirge) for use in adult and pediatric patients aged 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time ...
NIH Study Outlines Opportunities to Achieve Cancer Moonshot Goal of Reducing Cancer Mortality in the United States
Researchers from the National Institutes of Health (NIH) have outlined opportunities for achieving President Joe Biden and First Lady Jill Biden’s Cancer Moonshot national goal of reducing the cancer death rate by at least 50% over the next 25 years. A study published by Shiels et al in Cancer...
Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma
Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by Kendra et al at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Abstract...
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer
As reported in JAMA Oncology by Tang et al, the phase II EXTEND (External Beam Radiation to Eliminate Nominal Metastatic Disease) trial has shown that the addition of metastasis-directed therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic...
Yes, You Should Attend the 2023 ASCO Annual Meeting
The questions I am challenged to answer are twofold: (1) Should you attend the 2023 ASCO Annual Meeting? (2) If you attend, how is your time best spent? Most people agree scientific conferences are important venues for cancer researchers and clinicians to share and discuss research findings,...
Genetics Likely Caused My Small Cell Lung Cancer
When I was diagnosed with lung cancer, in 2007, I asked the physician not to tell me the type, stage, or prognosis. I was about to start nursing school and was aware enough about the disease to know that not many people survived. I’ve since discovered that I had stage 3B small cell lung cancer,...
Early-Stage Triple-Negative Breast Cancer: Optimizing Therapy
The management of early-stage triple-negative breast cancer has been evolving at a fast pace, thanks largely to the discovery that immune checkpoint blockade can be effective in this subtype. At the 2023 Miami Breast Cancer Conference, Priyanka Sharma, MD, Professor of Medicine, University of...
Interferon Alfa-2b May Substantially Increase Survival in Patients With Lymphomatoid Granulomatosis
Researchers have demonstrated that patients with low-grade lymphomatoid granulomatosis who were treated with the immunotherapy interferon alfa-2b may survive for a median of 20 years after diagnosis, according to a novel study published by Melani et al in The Lancet Haematology. The findings...
Primary Overall Survival Analysis of the ENZAMET Trial in Metastatic Hormone-Sensitive Prostate Cancer
As reported in The Lancet Oncology by Christopher J. Sweeney, MBBS, and colleagues, the primary overall survival analysis of the phase III ENZAMET trial showed a significant benefit with enzalutamide plus testosterone suppression vs standard nonsteroidal antiandrogen treatment plus testosterone...
Risk of Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer
In a phase II trial (ACOSOG Z11102/Alliance) reported in the Journal of Clinical Oncology, Judy C. Boughey, MD, and colleagues found that breast-conserving therapy was associated with a low rate of local recurrence in women with multiple ipsilateral breast cancer sites. Study Details A total of 204 ...
Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Julie E. Bauman, MD, MPH, and colleagues found that the combination of the antihepatocyte growth factor antibody ficlatuzumab and cetuximab was active in patients with cetuximab-resistant, recurrent or metastatic head and neck...
Addition of Immunotherapy to Chemotherapy Regimen May Increase Progression-Free Survival in Patients With Advanced or Recurrent Endometrial Cancer
Adding immunotherapy to standard chemotherapy may result in significantly longer progression-free survival for patients with advanced or recurrent endometrial cancer, according to the findings from two novel studies presented by Eskander et al and Mirza et al at the Society of Gynecologic Oncology...
Addition of Gemcitabine to Cisplatin and Intensity-Modulated Radiation Therapy May Improve Outcomes for Patients With Locally Advanced Vulvar Cancer
Researchers have found that concurrent treatment with gemcitabine as well as cisplatin and intensity-modulated radiation therapy may effectively increase the pathologic complete response rates in patients with locally advanced squamous cell carcinoma of the vulva, according to findings presented by ...
Naporafenib Plus Trametinib in Advanced NRAS-Mutant Melanoma
As reported in the Journal of Clinical Oncology by de Braud et al, findings in the expansion cohort of a phase Ib trial indicate activity with the combination of the BRAF/CRAF kinase inhibitor naporafenib and trametinib in patients with advanced or metastatic NRAS-mutant melanoma. Study Details In ...
Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma
As reported in The New England Journal of Medicine by Paula Rodriguez-Otero, MD, PhD, of Clínica Universidad de Navarra, Pamplona, Spain, and colleagues, an interim analysis of the phase III KarMMa-3 trial has shown superior progression-free survival with the B-cell maturation antigen–directed...
Sacituzumab Govitecan-hziy Achieves Response After Disease Progression on Immune Checkpoint Inhibitor in Metastatic Urothelial Cancer
Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy achieved an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer who experienced disease progression on an immune checkpoint inhibitor, according to the primary analysis of the...
Carl H. June, MD, FAACR, to Be Honored With 2023 AACR Award for Lifetime Achievement in Cancer Research
The American Associationfor Cancer Research (AACR) will award Carl H. June, MD, FAACR, Fellow of the AACR Academy, with the 2023 AACR Award for Lifetime Achievement in Cancer Research during the 2023 AACR Annual Meeting, April 14–19 in Orlando, Florida. Dr. June is the Richard W. Vague Professor in ...
Zanubrutinib Improves Progression-Free Survival vs Ibrutinib in Relapsed or Refractory CLL or SLL
As reported in The New England Journal of Medicine by Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute and Harvard University, and colleagues, the phase III ALPINE trial has shown significantly better progression-free survival with zanubrutinib, a Bruton’s tyrosine kinase (BTK)...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
FDA Grants Accelerated Approval to Retifanlimab-dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma
On March 22, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the PD-1 inhibitor retifanlimab-dlwr (Zynyz) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma. PODIUM-201 Safety and efficacy were evaluated in PODIUM-201...
Axitinib and Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma
In a single-center phase II trial reported in the Journal of Clinical Oncology, Renata Ferrarotto, MD, and colleagues found that the combination of axitinib and avelumab showed evidence of activity in patients with recurrent or metastatic adenoid cystic carcinoma. Study Details In the study, 28...
Neoadjuvant Dual Immunotherapy Plus Chemotherapy Improves Patient Outcomes in Operable Lung Cancer
In the phase II NEOSTAR trial, adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage, resectable non–small cell lung cancer (NSCLC). New findings from the NEOSTAR study,...
First ASCO Guideline for Immunotherapy and Targeted Therapy in Advanced Gastroesophageal Cancer Now Available
An ASCO expert panel has developed a comprehensive guideline for immunotherapy and targeted therapy in patients with advanced gastroesophageal cancer.1 The guideline is based on the many recent advances in immunotherapy and targeted therapy. “The role of immunotherapy has changed practice in the...
‘Best of SABCS’: Top 7 Picks From the 2022 Meeting by Jame Abraham, MD, FACP
Among the high-quality abstract presentations at the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCOPost asks our Associate Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman of ...
Blood Test May Identify Patients With AML at Greater Risk of Relapse After Bone Marrow Transplant
Researchers have found that screening for residual disease prior to a bone marrow transplant may help physicians identify which adult patients in remission from acute myeloid leukemia (AML) are at risk of relapsing after the procedure, according to a novel study published by Dillon et al in JAMA....
Phase III Trials Confirm Benefit of First-Line Anti–PD-1 Inhibition Plus Chemotherapy in Gastric Cancer
Two phase III trials evaluating the addition of drugs targeting PD-1 to chemotherapy—RATIONALE 305 and CheckMate 649—confirmed the benefit of this approach as first-line therapy for advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma, in findings presented at the 2023 ASCO GI...
Nivolumab Followed by Nivolumab/Ipilimumab Boosting in Nonresponders Among Previously Treated Patients With Advanced Urothelial Carcinoma
In a German-Austrian phase II study (TITAN-TCC) reported in The Lancet Oncology, Grimm et al found that a strategy of nivolumab monotherapy followed by immunotherapeutic boosting including high-dose ipilimumab in nivolumab nonresponders showed activity in patients with unresectable or metastatic...
